Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel/encequidar - Athenex

Drug Profile

Paclitaxel/encequidar - Athenex

Alternative Names: Encequidar/paclitaxel - Athenex; HM-30181A/paclitaxel - Athenex; HM30181AK - Athenex; Oraxol; Paclitaxel/HM-30181A - Athenex; Paclitaxel/HM30181-methanesulfonate monohydrate - Athenex

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Haemangiosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer
  • Phase II Cancer; Gastric cancer
  • Phase I/II Solid tumours
  • Phase I Haemangiosarcoma; Oesophageal cancer

Most Recent Events

  • 30 Oct 2019 Paclitaxel/encequidar - Athenex receives Orphan Drug status for Soft tissue sarcoma in European Union
  • 21 Aug 2019 Phase-I clinical trials in Gastric cancer (Combination therapy) in Singapore and Vietnam (PO), prior to August 2019 (PharmaEssentia pipeline, August 2019)
  • 21 Aug 2019 Registered for Breast cancer in Singapore, Vietnam, Taiwan (PO), prior to August 2019 (PharmaEssentia pipeline, August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top